Breaks Categories: News

TuesdayJul 01, 2025 9:20 am

CBDNewsBreaks – Golden Triangle Ventures Inc. (OTC: GTVH) Restructures $7 Million in Legacy Debt, Secures Repurchase Option

Golden Triangle Ventures (OTC: GTVH) (“GTV”) has completed a major restructuring of its capital structure and legacy debt obligations through an agreement with a new third-party investor, who acquired all outstanding notes previously held by the Company’s largest creditor, T&K Zarro, LLC. The transaction consolidates five debt instruments totaling over $7 million and grants GTVH the exclusive right to repurchase the full balance for $4 million, offering a significant discount. The move simplifies GTVH’s balance sheet, supports disciplined growth and strengthens financial positioning. To view the full press release, visit https://cnw.fm/Wj1LM About Golden Triangle Ventures Inc. Golden Triangle Ventures is a…

Continue Reading

TuesdayJun 24, 2025 3:14 pm

CBDNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Positive Preclinical Results for INM-901 in Alzheimer’s Neuroinflammation Model

InMed Pharmaceuticals (NASDAQ: INM), a pharmaceutical company developing small molecule drug candidates for diseases with high unmet medical needs, announced new preclinical data showing that INM-901 significantly reduces inflammation in ex vivo models of neuroinflammation. The compound demonstrated a dose-dependent and statistically significant reduction in pro-inflammatory cytokines IL-6, IL-1β, IL-2, KC/Gro, and inflammasome marker NLRP3—key factors in Alzheimer’s disease progression. Notably, the effects were independent of amyloid beta or tau pathology, highlighting INM-901’s broader potential in treating neurodegenerative diseases. The orally administered compound also targets CB1/CB2 receptors and PPARs and has shown improvements in cognition and behavior in long-term animal…

Continue Reading

ThursdayNov 21, 2024 11:30 am

CBDNewsBreaks – Golden Triangle Ventures Inc. (GTVH) to Host Spaces Event, Share Comprehensive Update on Destino Ranch

Golden Triangle Ventures (OTC: GTVH) (“GTV”) today announced its plans to host a Spaces call at 1:30 p.m. PST on Wednesday, Dec. 11, 2024, on the company’s official X account, @GTV_Inc. Steffan Dalsgaard, president of Golden Triangle Ventures and CEO of Lavish Entertainment, alongside Marco Moreno, president of Lavish Entertainment, will lead the event and deliver a comprehensive update on the company’s transformative flagship project — Destino Ranch. GTV’s wholly owned subsidiary Lavish Entertainment is spearheading the development of Destino Ranch, which is poised to become a world-renowned destination and premier experiential hospitality and entertainment venue, including immersive art installations,…

Continue Reading

ThursdayOct 24, 2024 12:45 pm

CBDNewsBreaks – CBD Life Sciences Inc. (CBDL) Poised to Become Game Changer in the Hemp Industry

CBD Life Sciences (OTC: CBDL) today announced its potential for explosive profits in a $70 billion industry and, with its innovative product line and strategic market positioning, standing ready to deliver unparalleled returns for shareholders. “The U.S. is on the verge of a historic shift. With the Biden administration, led by Vice President Kamala Harris, taking bold steps toward federal marijuana legalization, the opportunities for companies in the cannabis and CBD sectors are poised to skyrocket,” the announcement reads. “According to industry projections, the legal cannabis market in the U.S. is expected to surpass $70 billion by 2028, driven by…

Continue Reading

WednesdayOct 16, 2024 12:20 pm

CBDNewsBreaks – Software Effective Solutions Corp. (d/b/a MedCana) (SFWJ) Subsidiary Negotiating Pharma Cannabis Supply Deal with Australian Firm

Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ), a leading global infrastructure holding company focused on the pharmaceutical-grade cannabis industry, today announced that its Colombian subsidiary is in negotiations with an Australian pharmaceutical company to supply medical-grade cannabis. The agreement is expected to generate between $100,000 and $200,000 in monthly revenue once operations begin. MedCana's CEO, Jose Gabriel Diaz, emphasized the significance of this deal in the company’s ongoing global expansion aimed at meeting the rising demand for high-quality cannabis products. To view the full press release, visit https://cnw.fm/uIXJh About Software Effective Solutions Software Effective Solutions/MedCana is a holding company…

Continue Reading

WednesdayOct 09, 2024 12:35 pm

CBDNewsBreaks – Software Effective Solutions Corp. (d/b/a MedCana) (SFWJ) Releases Report on Series of Acquisitions, Multiple Cannabis Licenses

Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ), a leading global infrastructure holding company focused on the pharmaceutical-grade cannabis industry, is reporting on recent acquisitions and cannabis licenses associated with the acquisitions. According to the announcement, the new acquisitions and licenses, which will add $1.6 million to company assets for the third quarter, are designed to bolster the company's cannabis portfolio globally and solidify its position as a leading force in the cannabis sector. According to the announcement, the licenses include seven produce, process and sell CBD licenses; seven produce, process and sell THC licenses; seven fabrication of products containing…

Continue Reading

FridaySep 27, 2024 3:20 pm

CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Begin Human Pilot Study #3 Evaluating DehydraTECH-Processed Tirzepatide

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, announced Friday that it had received approval from an independent review board for its planned human pilot study #3. The approval signals that the company can begin the study, which aims to investigate the first ever DehydraTECH-processed version of tirzepatide, a dual action glucagon-like peptide (“GLP-1”) + glucose-dependent insulinotropic peptide (“GIP”), in an oral dose format. Tirzepatide is approved for use in the U.S. under the Eli Lilly(TM)-owned Zepbound(R) and Mounjaro(R) brands. Lexaria plans to begin subject enrollment shortly, with the company expecting to make an announcement as…

Continue Reading

ThursdaySep 12, 2024 12:05 pm

CBDNewsBreaks – Golden Triangle Ventures Inc. (GTVH) Announces Partnership to Boost Operational Capacity, Sustain Revenue Growth in Logistics Division

Golden Triangle Ventures (OTC: GTVH), a multifaceted consulting company, today announced a strategic partnership between LE Logistics, LLC, its wholly owned subsidiary, and West End Trucking, Inc. The partnership is expected to significantly boost the company’s asset base and operational capacity and set the stage for continued revenue growth and long-term success. Under the partnership, LE Logistics will manage and operate a fleet of 13 trucks and trailers under its own and West End’s licenses. Specifically, LE Logistics will handle all day-to-day logistics operations and create a robust system for fleet management, while West End will ensure compliance with all…

Continue Reading

ThursdaySep 05, 2024 11:16 am

CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Appoints Medical Device and Pharmaceutical Industries Veteran as New CEO

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced the appointment of Richard Christopher as the new CEO, effective August 31, 2024. Mr. Christopher is a recognized industry veteran with over three decades of experience in the medical device and pharmaceutical industries. He has domestic and international experience in leadership, operations, acquisitions/licensing, business development, strategic planning and capital markets. Mr. Christopher takes over from outgoing CEO, Chris Bunka, who has stepped aside from the role. Mr. Bunka remains as the Chairman of the Board of Directors and has been appointed Executive Strategic Advisor to the…

Continue Reading

TuesdaySep 03, 2024 12:24 pm

CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Material Transfer Agreement to Evaluate DehydraTECH(TM) Technology in Pre-Clinical Setting

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, has entered into a Materials Transfer Agreement with a pharmaceutical company. Under the terms of the agreement, the pharmaceutical company will evaluate Lexaria’s DehydraTECH(TM) technology in a pre-clinical setting. Lexaria will be responsible for formulating and supplying certain DehydraTECH compositions, with the pharmaceutical company evaluating the pharmacokinetics of these compositions in animal studies. According to the company, Lexaria has awarded the pharmaceutical company a temporary exclusive license option limited to specific DehydraTECH concepts and formulations under examination. The work is expected to be completed within roughly 6 months…

Continue Reading